Following more than a decade of Viagra campaigns starring men, the pharma giant made the switch to help put men with ED "at ease," Pfizer spokesman Steve Danehy told FiercePharmaMarketing in an email.
Want a surefire way to shake up a drug market? Introduce new medication options that make it easier for patients to manage their disease. MS drugmakers would know; their market is all of a sudden full of them.
For one, a game-changing trio of pills is providing an alternative to injections. Novartis' Gilenya hit first in September 2010, followed by Sanofi's Aubagio and Biogen Idec's Tecfidera. Two of those three, Gilenya and Tecfidera, nabbed spots on our list of Top 15 drug launch superstars after hitting the ground running. They're primed to keep moving up the food chain, too.
Drugmakers raise U.S. prices to make more money. This isn't a surprise to anyone. It's a basic business strategy, and the U.S. market is among the few where pharma companies still have considerable pricing power. But thanks to a steady flow of expensive new cancer therapies--and a public brouhaha over the cost of next-gen treatments for hepatitis C--drug prices are on center stage.
Prominent cancer doctors have balked at adopting a new Sanofi drug, Zaltrap, because they decided its benefits weren't worth the cost. Pharmacy benefits managers, notably Express Scripts, have nixed drugs from their formularies in favor of competing--and less expensive--options. And Gilead Sciences' pricing poster child Sovaldi has private payers and government programs so spooked, they're considering limiting its use to the sickest patients, at least until they can use soon-to-be-approved rivals to negotiate better pricing. Click here to read the full report on FiercePharmaMarketing >>
This is the best FiercePharma reading experience we've ever created. Swipe right-to-left within articles to quickly scan the latest news. Get breaking news alerts sent to your mobile device so you're the first to know when a major story unfolds. Download it today; the app is an essential complement to our e-mail newsletter and website.
Have something to say? Join the conversation at
FiercePharma's LinkedIn group.
If the personal doesn't work, then get impersonal. That's the message of a new look at doctors' preferences for listening to drugmakers. Some doctors who aren't interested in face-to-face rep meetings are plenty accessible when pharma knocks on their doors electronically. Read more >>
A few things are certain about the Sunshine Act data that hit the Internet Tuesday afternoon. One, it's incomplete. Two, it's controversial. Three, the numbers are pretty staggering, with $3.5 billion in payments to 546,000 doctors and 1,360 research institutions over a 5-month period.
In an order filed Tuesday, U.S. District Judge Paul Gardephe refused to dismiss claims that Novartis lavished entertainment on certain physicians in return for increased prescriptions.
Sucampo and Takeda may not be the first to launch a DTC campaign for a chronic idiopathic constipation (CIC) treatment. But the team, which markets Amitiza, is doing things a little differently.
Rare disease drugs can cost as much as $400,000 a year, and those hefty price tags have sparked a lively debate about the cost of treating rare diseases over the long term.
Hey, young women: You have plans. Dreams. Goals. And by the way, getting pregnant unexpectedly could throw those visions for your future under the bus. That's the (implicit) message in several newly launched campaigns from Pfizer and Bayer Healthcare, including a pitch for Bayer's new device Skyla supported by a fellow millennial, the actress Zosia Mamet of Girls fame.